Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 16 | 2024 | 2174 | 2.250 |
Why?
|
| Liver Neoplasms | 16 | 2024 | 4811 | 1.650 |
Why?
|
| Liver Transplantation | 7 | 2023 | 1184 | 1.370 |
Why?
|
| Hepatitis C, Chronic | 5 | 2023 | 469 | 1.090 |
Why?
|
| Bile Duct Neoplasms | 3 | 2023 | 498 | 0.910 |
Why?
|
| Famotidine | 1 | 2022 | 16 | 0.860 |
Why?
|
| Hepatitis C | 3 | 2022 | 551 | 0.810 |
Why?
|
| Sarcopenia | 1 | 2023 | 113 | 0.810 |
Why?
|
| End Stage Liver Disease | 2 | 2023 | 186 | 0.810 |
Why?
|
| Frailty | 1 | 2023 | 133 | 0.760 |
Why?
|
| Liver Diseases | 2 | 2023 | 605 | 0.760 |
Why?
|
| Cholangiocarcinoma | 2 | 2023 | 501 | 0.750 |
Why?
|
| Malnutrition | 1 | 2023 | 226 | 0.730 |
Why?
|
| Hepatitis B, Chronic | 1 | 2022 | 139 | 0.720 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2020 | 44 | 0.700 |
Why?
|
| Hepatitis, Alcoholic | 3 | 2024 | 25 | 0.510 |
Why?
|
| Liver Cirrhosis | 8 | 2024 | 1033 | 0.420 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 2307 | 0.330 |
Why?
|
| Fasting | 2 | 2020 | 350 | 0.310 |
Why?
|
| Pancreatitis | 2 | 2010 | 293 | 0.310 |
Why?
|
| Alcohol Drinking | 2 | 2021 | 600 | 0.300 |
Why?
|
| Antiviral Agents | 5 | 2023 | 1255 | 0.290 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2023 | 333 | 0.280 |
Why?
|
| Graft Survival | 2 | 2020 | 1092 | 0.270 |
Why?
|
| Risk Factors | 13 | 2024 | 18047 | 0.270 |
Why?
|
| Retrospective Studies | 17 | 2024 | 39800 | 0.250 |
Why?
|
| Humans | 39 | 2024 | 271941 | 0.240 |
Why?
|
| alpha-Fetoproteins | 2 | 2023 | 256 | 0.230 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2023 | 29 | 0.220 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2023 | 84 | 0.210 |
Why?
|
| Hepatitis B e Antigens | 1 | 2022 | 13 | 0.210 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2023 | 94 | 0.210 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2022 | 28 | 0.210 |
Why?
|
| Hemochromatosis | 1 | 2022 | 39 | 0.200 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2023 | 62 | 0.200 |
Why?
|
| Hypertension, Portal | 1 | 2023 | 129 | 0.200 |
Why?
|
| Angiopoietin-2 | 1 | 2022 | 37 | 0.200 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2022 | 89 | 0.200 |
Why?
|
| Dietary Exposure | 1 | 2021 | 3 | 0.200 |
Why?
|
| Nitroso Compounds | 1 | 2021 | 18 | 0.200 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2021 | 20 | 0.200 |
Why?
|
| Diet, Western | 1 | 2021 | 23 | 0.190 |
Why?
|
| Diet Surveys | 1 | 2021 | 119 | 0.190 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2021 | 64 | 0.190 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2021 | 84 | 0.180 |
Why?
|
| Hepatitis | 1 | 2021 | 94 | 0.180 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2022 | 173 | 0.180 |
Why?
|
| Hepatitis B virus | 1 | 2022 | 225 | 0.180 |
Why?
|
| DNA, Viral | 1 | 2022 | 764 | 0.170 |
Why?
|
| Dietary Fats | 1 | 2021 | 350 | 0.170 |
Why?
|
| Cause of Death | 1 | 2022 | 787 | 0.170 |
Why?
|
| Steroids | 1 | 2021 | 375 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 430 | 0.170 |
Why?
|
| Circadian Clocks | 1 | 2020 | 61 | 0.170 |
Why?
|
| United States | 8 | 2024 | 16053 | 0.160 |
Why?
|
| Vegetables | 1 | 2021 | 330 | 0.160 |
Why?
|
| Hepatitis B | 1 | 2021 | 274 | 0.160 |
Why?
|
| Radiography | 1 | 2023 | 1993 | 0.160 |
Why?
|
| Prognosis | 7 | 2024 | 22550 | 0.150 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2019 | 192 | 0.150 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2021 | 441 | 0.150 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 606 | 0.150 |
Why?
|
| Case-Control Studies | 6 | 2024 | 6236 | 0.150 |
Why?
|
| Aged | 14 | 2024 | 73494 | 0.150 |
Why?
|
| Adult | 15 | 2024 | 81889 | 0.140 |
Why?
|
| Biomarkers | 3 | 2022 | 5114 | 0.140 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 374 | 0.140 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2017 | 103 | 0.140 |
Why?
|
| Proteome | 1 | 2020 | 573 | 0.140 |
Why?
|
| Acute Kidney Injury | 1 | 2024 | 784 | 0.140 |
Why?
|
| Liver | 2 | 2017 | 3124 | 0.130 |
Why?
|
| Treatment Outcome | 7 | 2023 | 33874 | 0.130 |
Why?
|
| Male | 18 | 2024 | 128995 | 0.130 |
Why?
|
| Tissue Donors | 1 | 2020 | 812 | 0.130 |
Why?
|
| Severity of Illness Index | 5 | 2024 | 4399 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 2333 | 0.130 |
Why?
|
| Time Factors | 4 | 2021 | 13130 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 10365 | 0.120 |
Why?
|
| Kidney | 2 | 2017 | 2267 | 0.120 |
Why?
|
| Metabolomics | 1 | 2017 | 507 | 0.110 |
Why?
|
| Middle Aged | 19 | 2024 | 90427 | 0.110 |
Why?
|
| Diet | 1 | 2021 | 1489 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2020 | 1904 | 0.100 |
Why?
|
| Female | 17 | 2024 | 149187 | 0.100 |
Why?
|
| Sustained Virologic Response | 2 | 2023 | 62 | 0.100 |
Why?
|
| Obesity | 2 | 2023 | 2958 | 0.090 |
Why?
|
| North America | 2 | 2024 | 341 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 641 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 5755 | 0.090 |
Why?
|
| Midazolam | 1 | 2010 | 72 | 0.090 |
Why?
|
| Hepacivirus | 2 | 2023 | 423 | 0.090 |
Why?
|
| Propofol | 1 | 2010 | 80 | 0.080 |
Why?
|
| Risk Assessment | 5 | 2023 | 6883 | 0.080 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2010 | 172 | 0.080 |
Why?
|
| Fentanyl | 1 | 2010 | 153 | 0.080 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2008 | 27 | 0.080 |
Why?
|
| Hypnotics and Sedatives | 1 | 2010 | 220 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2022 | 13402 | 0.080 |
Why?
|
| Fascioliasis | 1 | 2007 | 7 | 0.070 |
Why?
|
| Fasciola hepatica | 1 | 2007 | 6 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2022 | 5118 | 0.070 |
Why?
|
| Endoscopy, Digestive System | 1 | 2008 | 210 | 0.070 |
Why?
|
| Rectal Diseases | 1 | 2006 | 57 | 0.070 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2007 | 123 | 0.060 |
Why?
|
| Catheterization | 1 | 2008 | 425 | 0.060 |
Why?
|
| Drainage | 1 | 2008 | 448 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2024 | 9494 | 0.060 |
Why?
|
| Pancreas | 1 | 2007 | 746 | 0.050 |
Why?
|
| Renal Replacement Therapy | 1 | 2024 | 152 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 10750 | 0.050 |
Why?
|
| Celiac Disease | 1 | 2003 | 80 | 0.050 |
Why?
|
| Gastric Mucosa | 1 | 2006 | 659 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 32 | 0.050 |
Why?
|
| Acute Disease | 1 | 2007 | 2514 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2024 | 497 | 0.050 |
Why?
|
| Intestinal Neoplasms | 1 | 2003 | 202 | 0.050 |
Why?
|
| Health Care Rationing | 1 | 2021 | 79 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2023 | 349 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2021 | 265 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 176 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 108 | 0.040 |
Why?
|
| Incidence | 2 | 2021 | 5861 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2020 | 591 | 0.040 |
Why?
|
| Adiposity | 1 | 2020 | 238 | 0.040 |
Why?
|
| Child | 1 | 2020 | 30499 | 0.040 |
Why?
|
| Attitude | 1 | 2019 | 163 | 0.040 |
Why?
|
| Cytoskeleton | 1 | 2020 | 304 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 505 | 0.040 |
Why?
|
| Immune System | 1 | 2020 | 277 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 391 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 441 | 0.040 |
Why?
|
| Life Style | 1 | 2021 | 623 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 498 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2021 | 2335 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2022 | 2287 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2017 | 606 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2020 | 1159 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 3469 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 2866 | 0.030 |
Why?
|
| Cognition | 1 | 2020 | 982 | 0.030 |
Why?
|
| Glucose | 1 | 2020 | 1245 | 0.030 |
Why?
|
| Proteomics | 1 | 2020 | 1437 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 4639 | 0.020 |
Why?
|
| DNA Repair | 1 | 2020 | 1912 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 1534 | 0.020 |
Why?
|
| Inflammation | 1 | 2020 | 2534 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2017 | 9325 | 0.020 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2010 | 151 | 0.020 |
Why?
|
| Adolescent | 3 | 2020 | 32687 | 0.020 |
Why?
|
| Equipment Safety | 1 | 2008 | 66 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 13936 | 0.020 |
Why?
|
| Choristoma | 1 | 2006 | 87 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2008 | 509 | 0.020 |
Why?
|
| Endosonography | 1 | 2008 | 549 | 0.020 |
Why?
|
| Equipment Design | 1 | 2008 | 1207 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 7976 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 6270 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 6210 | 0.010 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2006 | 372 | 0.010 |
Why?
|
| United Kingdom | 1 | 2003 | 289 | 0.010 |
Why?
|
| Health Surveys | 1 | 2003 | 402 | 0.010 |
Why?
|
| Smoking | 1 | 2010 | 2538 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 545 | 0.010 |
Why?
|
| Animals | 2 | 2020 | 62823 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 36054 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 31060 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 1065 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 15269 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 7791 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 7929 | 0.010 |
Why?
|